2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gra...
2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a post hoc analysis
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundIn the Phase 3 MycarinG (NCT03971422) study, one cycle (six once-weekly subcutaneous infusions) of rozanolixizumab 7mg/kg or 10mg/kg significantly improved myasthenia gravis (MG)-specific outcomes versus placebo. After MycarinG, patients could enrol in open-label extensions MG0004 (NCT04124965) or MG0007 (NCT04650854). We evaluated respon...
Alternative Titles
Full title
2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a post hoc analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_53c539d4025a4c2ca5ce09720ffd826a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_53c539d4025a4c2ca5ce09720ffd826a
Other Identifiers
E-ISSN
2632-6140
DOI
10.1136/bmjno-2024-ANZAN.36
